Trial Information - Phase III
Tropion-Lung08: A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations
Disease Specifics: (NSCLC)
Protocol ID: DS1062-A-U304
Sponsor: Daiichi Sankyo, Inc
Status: PENDING OPEN
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
